



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

August 2018





© 2018 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

**BC Centre for Excellence in HIV/AIDS
Drug Treatment Program**

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

August 2018

N = 7287



Health Authority	Male	Female	All
FRASER	1411	402	1813
INTERIOR	390	99	489
NORTHERN	132	81	213
VANCOUVER COASTAL	3398	459	3857
VANCOUVER ISLAND	727	149	876
	6058	1190	7248
		Unknown/not stated:	39
		Total:	7287

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (August 2013 - August 2018)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (August 2013 - August 2018)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (August 2013 - August 2018)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (August 2013 - August 2018)






1.6 Percent Distribution of Active Participants by CD4 Count (August 2013 - August 2018)






1.7 Percent Distribution of Inactive Participants by CD4 Count
(August 2013 - August 2018)






1.8 Active and Inactive Participants (August 2013 - August 2018)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (August 2013 - August 2018)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (August 2013 - August 2018)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(August 2013 - August 2018)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (August 2013 - August 2018)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(August 2013 - August 2018)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (August 2013 - August 2018)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(August 2013 - August 2018)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (August 2013 - August 2018)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(August 2013 - August 2018)






1.18 Baseline CD4 for Antiretroviral First Starts (August 2013 - August 2018)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(August 2013 - August 2018)**






1.20 Cumulative Resistance Testing Results by Resistance Category (August 2013 - August 2018)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (August 2013 - August 2018)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2018
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	26	5	0	5	5	760	5	<40	3
1988	27	7	0	7	7	510	7	<40	3
1989	25	55	2	57	48	475	54	<40	3
1990	24	58	1	59	55	500	59	<40	3
1991	24	38	2	40	28	585	37	<40	3
1992	24	64	6	70	56	575	69	<40	3
1993	23	134	15	149	136	575	142	<40	3
1994	22	82	12	94	76	590	88	<40	3
1995	22	130	21	151	127	580	146	<40	3
1996	19	364	56	420	359	570	401	<40	3
1997	18	295	34	329	289	640	310	<40	3
1998	17	207	44	251	212	560	238	<40	3
1999	17	168	39	207	180	560	198	<40	3
2000	17	126	33	159	134	590	153	<40	3
2001	17	123	33	156	125	550	147	<40	3
2002	16	128	28	156	133	570	152	<40	3
2003	15	162	27	189	164	585	185	<40	3
2004	14	169	42	211	170	600	200	<40	3
2005	13	185	46	231	198	610	222	<40	3
2006	12	195	41	236	188	570	225	<40	3
2007	11	263	50	313	266	600	297	<40	3
2008	10	299	67	366	309	650	346	<40	3
2009	9	324	75	399	344	660	377	<40	3
2010	8	289	67	356	306	640	339	<40	3
2011	7	336	74	410	345	660	379	<40	3
2012	6	284	66	350	289	700	328	<40	3
2013	5	281	68	349	292	670	334	<40	3
2014	4	292	49	341	286	700	328	<40	3
2015	3	296	51	347	281	650	321	<40	3
2016	2	292	61	353	291	680	335	<40	3
2017	1	245	43	288	242	620	272	<40	3
2018	0	172	36	208	187	560	203	<40	3
Total:		6068	1189	7257					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2017	7182	747	2326	<40	2077	590
FEB-2017	7134	754	1914	<40	1739	590
MAR-2017	7186	744	2204	<40	2018	600
APR-2017	7178	746	1965	<40	1770	590
MAY-2017	7224	744	2276	<40	2057	590
JUN-2017	7245	752	2120	<40	1953	596
JUL-2017	7241	753	1965	<40	1788	580
AUG-2017	7266	757	2106	<40	1884	590
SEP-2017	7222	762	2042	<40	1837	610
OCT-2017	7244	770	2186	<40	1938	610
NOV-2017	7241	766	2073	<40	1873	610
DEC-2017	7227	775	1740	<40	1536	610
JAN-2018	7292	756	2384	<40	2102	610
FEB-2018	7256	765	1904	<40	1737	610
MAR-2018	7281	774	2050	<40	1819	618
APR-2018	7266	781	2081	<40	1820	620
MAY-2018	7288	781	2149	<40	1894	600
JUN-2018	7295	795	2010	<40	1752	620
JUL-2018	7295	797	2036	<40	1716	600
AUG-2018	7287	801	2090	<40	1760	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2017	1403	3151	88	140	80	417
FEB-2017	1456	2851	80	1874	70	400
MAR-2017	1409	3132	99	635	89	380
APR-2017	1424	3090	94	545	85	420
MAY-2017	1396	3277	85	180	75	420
JUN-2017	1386	3361	76	197	68	485
JUL-2017	1407	3248	68	376	61	520
AUG-2017	1400	3313	78	160	68	495
SEP-2017	1457	3056	74	323	66	415
OCT-2017	1431	3208	91	218	80	470
NOV-2017	1450	3126	79	144	68	360
DEC-2017	1481	3037	60	53	50	382
JAN-2018	1434	3277	78	872	70	365
FEB-2018	1479	3096	81	264	67	450
MAR-2018	1463	3167	75	59	68	495
APR-2018	1482	3125	72	634	60	500
MAY-2018	1465	3207	91	<40	81	460
JUN-2018	1471	3233	66	4750	62	440
JUL-2018	1481	3218	71	<40	56	570
AUG-2018	1523	3095	66	52	53	480

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2017	7140	1403	21	21	141	142	-6	12876
FEB-2017	7102	1456	10	24	136	182	-38	12910
MAR-2017	7147	1409	17	19	189	139	45	12936
APR-2017	7139	1424	12	20	143	151	-8	12968
MAY-2017	7194	1396	7	22	170	126	55	13002
JUN-2017	7210	1386	10	24	151	138	16	13032
JUL-2017	7202	1407	7	14	134	143	-8	13051
AUG-2017	7229	1400	10	25	156	137	27	13081
SEP-2017	7185	1457	12	16	137	180	-44	13110
OCT-2017	7212	1431	7	6	184	151	27	13123
NOV-2017	7206	1450	16	19	142	148	-6	13158
DEC-2017	7197	1481	5	18	157	175	-9	13189
JAN-2018	7252	1434	13	12	192	128	55	13218
FEB-2018	7220	1479	11	27	123	168	-32	13255
MAR-2018	7241	1463	17	22	153	133	21	13283
APR-2018	7231	1482	13	14	152	159	-10	13304
MAY-2018	7259	1465	9	12	171	144	28	13329
JUN-2018	7260	1471	13	16	149	149	1	13351
JUL-2018	7258	1481	13	15	156	157	-2	13378
AUG-2018	7257	1523	9	27	155	172	-1	13417

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2017	61	6615	443	63	7182	0.85%	92.11%	6.17%	0.88%	100.00%
FEB-2017	60	6579	440	55	7134	0.84%	92.22%	6.17%	0.77%	100.00%
MAR-2017	60	6629	439	58	7186	0.83%	92.25%	6.11%	0.81%	100.00%
APR-2017	58	6633	428	59	7178	0.81%	92.41%	5.96%	0.82%	100.00%
MAY-2017	62	6665	438	59	7224	0.86%	92.26%	6.06%	0.82%	100.00%
JUN-2017	57	6691	438	59	7245	0.79%	92.35%	6.05%	0.81%	100.00%
JUL-2017	61	6685	433	62	7241	0.84%	92.32%	5.98%	0.86%	100.00%
AUG-2017	61	6696	448	61	7266	0.84%	92.16%	6.17%	0.84%	100.00%
SEP-2017	57	6677	431	57	7222	0.79%	92.45%	5.97%	0.79%	100.00%
OCT-2017	58	6691	438	57	7244	0.80%	92.37%	6.05%	0.79%	100.00%
NOV-2017	59	6681	445	56	7241	0.81%	92.27%	6.15%	0.77%	100.00%
DEC-2017	58	6666	447	56	7227	0.80%	92.24%	6.19%	0.77%	100.00%
JAN-2018	58	6728	451	55	7292	0.80%	92.27%	6.18%	0.75%	100.00%
FEB-2018	61	6685	451	59	7256	0.84%	92.13%	6.22%	0.81%	100.00%
MAR-2018	62	6710	453	56	7281	0.85%	92.16%	6.22%	0.77%	100.00%
APR-2018	58	6701	449	58	7266	0.80%	92.22%	6.18%	0.80%	100.00%
MAY-2018	62	6712	456	58	7288	0.85%	92.10%	6.26%	0.80%	100.00%
JUN-2018	60	6728	449	58	7295	0.82%	92.23%	6.15%	0.80%	100.00%
JUL-2018	52	6728	460	55	7295	0.71%	92.23%	6.31%	0.75%	100.00%
AUG-2018	53	6724	454	56	7287	0.73%	92.27%	6.23%	0.77%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	13 41%	3068 44%	13 41%	2772 40%	0 0%	75 1%	0 0%	5 0%	0 0%	6 0%	0 0%	46 1%	19 59%	4051 58%
FEB-2017	12 35%	3074 44%	10 29%	2783 40%	1 3%	71 1%	0 0%	5 0%	0 0%	6 0%	0 0%	50 1%	22 65%	3982 58%
MAR-2017	7 27%	3105 45%	7 27%	2824 41%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	0 0%	78 1%	19 73%	4000 57%
APR-2017	13 41%	3114 45%	12 38%	2834 41%	1 3%	68 1%	0 0%	6 0%	0 0%	6 0%	0 0%	96 1%	19 59%	3962 57%
MAY-2017	9 26%	3159 45%	9 26%	2881 41%	0 0%	73 1%	0 0%	6 0%	0 0%	5 0%	1 3%	119 2%	24 71%	3930 56%
JUN-2017	6 20%	3169 45%	6 20%	2902 41%	0 0%	71 1%	0 0%	6 0%	0 0%	5 0%	2 7%	143 2%	22 73%	3898 55%
JUL-2017	7 37%	3198 46%	7 37%	2928 42%	0 0%	72 1%	0 0%	6 0%	0 0%	5 0%	0 0%	161 2%	12 63%	3861 55%
AUG-2017	6 20%	3224 46%	4 13%	2958 42%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	2 7%	171 2%	23 77%	3838 54%
SEP-2017	10 34%	3213 46%	10 34%	2950 42%	0 0%	66 1%	0 0%	5 0%	0 0%	4 0%	3 10%	207 3%	16 55%	3775 54%
OCT-2017	5 38%	3241 46%	5 38%	2983 42%	0 0%	65 1%	0 0%	4 0%	0 0%	4 0%	2 15%	245 3%	6 46%	3715 53%
NOV-2017	9 26%	3281 47%	8 23%	3025 43%	0 0%	65 1%	0 0%	5 0%	0 0%	4 0%	1 3%	265 4%	25 71%	3661 52%
DEC-2017	10 32%	3286 47%	10 32%	3032 43%	0 0%	64 1%	0 0%	5 0%	0 0%	4 0%	1 3%	272 4%	22 71%	3612 52%
JAN-2018	10 36%	3319 47%	9 32%	3075 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 7%	292 4%	16 57%	3635 51%
FEB-2018	13 35%	3320 47%	12 32%	3078 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	299 4%	25 68%	3587 51%
MAR-2018	10 36%	3341 47%	10 36%	3105 44%	0 0%	60 1%	0 0%	4 0%	0 0%	4 0%	0 0%	311 4%	18 64%	3569 50%
APR-2018	5 24%	3348 47%	5 24%	3116 44%	0 0%	56 1%	0 0%	3 0%	0 0%	4 0%	2 10%	333 5%	14 67%	3541 50%
MAY-2018	9 39%	3355 47%	8 35%	3129 44%	1 4%	57 1%	0 0%	5 0%	0 0%	4 0%	1 4%	351 5%	13 57%	3518 50%
JUN-2018	6 30%	3373 48%	6 30%	3149 44%	0 0%	54 1%	0 0%	5 0%	0 0%	3 0%	1 5%	380 5%	13 65%	3488 49%
JUL-2018	7 27%	3399 48%	7 27%	3176 45%	0 0%	51 1%	0 0%	5 0%	0 0%	3 0%	4 15%	398 6%	15 58%	3452 49%
AUG-2018	13 33%	3395 48%	14 36%	3183 45%	0 0%	50 1%	0 0%	4 0%	0 0%	3 0%	2 5%	414 6%	23 59%	3411 48%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2017	19	59%	3828	55%
FEB-2017	22	65%	3771	55%
MAR-2017	19	73%	3803	55%
APR-2017	19	59%	3791	55%
MAY-2017	25	74%	3795	54%
JUN-2017	24	80%	3797	54%
JUL-2017	12	63%	3770	54%
AUG-2017	24	80%	3767	53%
SEP-2017	19	66%	3740	53%
OCT-2017	7	54%	3731	53%
NOV-2017	26	74%	3693	53%
DEC-2017	21	68%	3665	52%
JAN-2018	18	64%	3711	52%
FEB-2018	24	65%	3681	52%
MAR-2018	18	64%	3675	52%
APR-2018	16	76%	3663	52%
MAY-2018	14	61%	3664	52%
JUN-2018	14	70%	3665	52%
JUL-2018	19	73%	3654	52%
AUG-2018	25	64%	3643	51%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	0 0%	9 0%	2 14%	1558 50%	12 86%	1313 42%	0 0%	247 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
FEB-2017	0 0%	9 0%	3 19%	1518 49%	12 75%	1307 43%	1 6%	236 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
MAR-2017	0 0%	8 0%	1 8%	1513 49%	11 92%	1329 43%	0 0%	232 8%	0 0%	2 0%	0 0%	1 0%	0 0%	12 0%
APR-2017	0 0%	8 0%	0 0%	1484 49%	5 71%	1318 43%	2 29%	231 8%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2017	0 0%	9 0%	0 0%	1462 48%	14 100%	1350 44%	0 0%	227 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUN-2017	0 0%	9 0%	2 18%	1453 48%	9 82%	1359 45%	0 0%	221 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUL-2017	0 0%	9 0%	0 0%	1439 47%	6 100%	1359 45%	0 0%	218 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
AUG-2017	0 0%	9 0%	1 5%	1417 47%	21 95%	1396 46%	0 0%	216 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
SEP-2017	0 0%	9 0%	0 0%	1388 46%	8 100%	1389 46%	0 0%	210 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
OCT-2017	0 0%	8 0%	0 0%	1364 46%	6 100%	1396 47%	0 0%	207 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
NOV-2017	0 0%	8 0%	1 8%	1324 45%	10 83%	1392 48%	1 8%	206 7%	0 0%	3 0%	0 0%	1 0%	0 0%	10 0%
DEC-2017	0 0%	7 0%	1 7%	1295 45%	14 93%	1397 48%	0 0%	197 7%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JAN-2018	0 0%	8 0%	3 30%	1318 45%	7 70%	1418 48%	0 0%	195 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1259 44%	15 100%	1422 49%	0 0%	189 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1248 43%	10 91%	1439 50%	0 0%	189 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
APR-2018	0 0%	6 0%	0 0%	1224 43%	11 100%	1437 50%	0 0%	182 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2018	0 0%	7 0%	0 0%	1212 43%	5 100%	1443 51%	0 0%	180 6%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JUN-2018	0 0%	7 0%	1 8%	1191 42%	11 92%	1436 51%	0 0%	177 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
JUL-2018	0 0%	7 0%	2 18%	1170 42%	8 73%	1445 52%	1 9%	170 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
AUG-2018	0 0%	7 0%	5 31%	1154 42%	11 69%	1427 52%	0 0%	165 6%	0 0%	1 0%	0 0%	1 0%	0 0%	8 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2017	0	0%	1	0%
FEB-2017	0	0%	1	0%
MAR-2017	0	0%	1	0%
APR-2017	0	0%	1	0%
MAY-2017	0	0%	1	0%
JUN-2017	0	0%	1	0%
JUL-2017	0	0%	1	0%
AUG-2017	0	0%	1	0%
SEP-2017	0	0%	1	0%
OCT-2017	0	0%	1	0%
NOV-2017	0	0%	1	0%
DEC-2017	0	0%	1	0%
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%
APR-2018	0	0%	1	0%
MAY-2018	0	0%	1	0%
JUN-2018	0	0%	1	0%
JUL-2018	0	0%	1	0%
AUG-2018	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	4 80%	928 41%	0 0%	292 13%	1 20%	799 35%	0 0%	269 12%
FEB-2017	4 80%	907 40%	0 0%	280 12%	0 0%	791 35%	1 20%	266 12%
MAR-2017	1 50%	897 40%	0 0%	279 13%	0 0%	790 35%	1 50%	265 12%
APR-2017	4 44%	888 40%	0 0%	273 12%	1 11%	787 36%	4 44%	271 12%
MAY-2017	3 75%	877 40%	0 0%	274 12%	0 0%	783 35%	1 25%	279 13%
JUN-2017	3 100%	853 39%	0 0%	270 12%	0 0%	782 36%	0 0%	288 13%
JUL-2017	2 100%	838 39%	0 0%	264 12%	0 0%	779 36%	0 0%	283 13%
AUG-2017	1 100%	821 38%	0 0%	268 12%	0 0%	777 36%	0 0%	285 13%
SEP-2017	4 50%	808 38%	0 0%	264 12%	1 13%	774 36%	3 38%	296 14%
OCT-2017	1 100%	802 38%	0 0%	267 13%	0 0%	768 36%	0 0%	299 14%
NOV-2017	5 71%	800 38%	0 0%	269 13%	0 0%	767 36%	2 29%	300 14%
DEC-2017	3 75%	793 38%	0 0%	263 12%	0 0%	758 36%	1 25%	301 14%
JAN-2018	3 50%	779 37%	1 17%	263 13%	2 33%	757 36%	0 0%	302 14%
FEB-2018	3 75%	771 37%	0 0%	257 12%	0 0%	749 36%	1 25%	306 15%
MAR-2018	1 33%	758 37%	0 0%	250 12%	0 0%	736 36%	2 67%	311 15%
APR-2018	1 50%	746 37%	0 0%	245 12%	0 0%	731 36%	1 50%	318 16%
MAY-2018	4 67%	725 36%	1 17%	252 12%	0 0%	727 36%	1 17%	316 16%
JUN-2018	1 50%	722 36%	0 0%	248 12%	0 0%	725 36%	1 50%	314 16%
JUL-2018	3 60%	723 36%	0 0%	243 12%	0 0%	717 36%	2 40%	314 16%
AUG-2018	2 100%	715 36%	0 0%	238 12%	0 0%	715 36%	0 0%	308 16%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	13 81%	1518 53%	3 19%	587 20%	0 0%	52 2%	0 0%	756 26%	0 0%	1 0%
FEB-2017	14 78%	1560 54%	4 22%	588 20%	0 0%	48 2%	0 0%	732 25%	0 0%	1 0%
MAR-2017	13 87%	1620 55%	2 13%	601 20%	0 0%	49 2%	0 0%	732 25%	0 0%	1 0%
APR-2017	14 78%	1655 55%	4 22%	596 20%	0 0%	50 2%	0 0%	722 24%	0 0%	1 0%
MAY-2017	19 86%	1726 57%	3 14%	602 20%	0 0%	47 2%	0 0%	715 23%	0 0%	1 0%
JUN-2017	12 75%	1757 57%	3 19%	596 19%	0 0%	49 2%	1 6%	713 23%	0 0%	1 0%
JUL-2017	8 73%	1791 58%	3 27%	592 19%	0 0%	48 2%	0 0%	705 23%	0 0%	1 0%
AUG-2017	13 72%	1824 58%	4 22%	596 19%	0 0%	49 2%	1 6%	707 22%	0 0%	1 0%
SEP-2017	10 71%	1833 58%	4 29%	600 19%	0 0%	50 2%	0 0%	700 22%	0 0%	1 0%
OCT-2017	8 89%	1879 59%	1 11%	608 19%	0 0%	48 1%	0 0%	708 22%	0 0%	0 0%
NOV-2017	14 67%	1939 60%	5 24%	611 19%	0 0%	49 2%	2 10%	701 22%	0 0%	0 0%
DEC-2017	11 69%	1958 60%	5 31%	603 18%	0 0%	48 1%	0 0%	689 21%	0 0%	0 0%
JAN-2018	9 47%	2006 60%	8 42%	631 19%	0 0%	46 1%	2 11%	688 21%	0 0%	0 0%
FEB-2018	16 70%	2027 60%	6 26%	642 19%	0 0%	45 1%	1 4%	676 20%	0 0%	0 0%
MAR-2018	14 93%	2061 61%	1 7%	646 19%	0 0%	43 1%	0 0%	674 20%	0 0%	0 0%
APR-2018	8 73%	2106 61%	3 27%	654 19%	0 0%	44 1%	0 0%	681 20%	0 0%	0 0%
MAY-2018	13 65%	2140 61%	4 20%	666 19%	1 5%	42 1%	3 15%	675 19%	0 0%	0 0%
JUN-2018	7 64%	2175 62%	3 27%	675 19%	0 0%	42 1%	1 9%	678 19%	0 0%	0 0%
JUL-2018	7 58%	2209 62%	4 33%	673 19%	0 0%	43 1%	1 8%	677 19%	0 0%	0 0%
AUG-2018	23 79%	2255 63%	5 17%	670 19%	0 0%	42 1%	1 3%	671 19%	0 0%	0 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2017	2155	30.01	1793	24.97	2135	29.73	139	1.94	63	0.88	897	12.49
FEB-2017	2125	29.79	1772	24.84	2165	30.35	133	1.86	55	0.77	884	12.39
MAR-2017	2133	29.68	1754	24.41	2223	30.94	134	1.86	58	0.81	884	12.30
APR-2017	2109	29.38	1744	24.30	2260	31.49	133	1.85	59	0.82	873	12.16
MAY-2017	2108	29.18	1737	24.04	2308	31.95	132	1.83	59	0.82	880	12.18
JUN-2017	2115	29.19	1719	23.73	2349	32.42	132	1.82	59	0.81	871	12.02
JUL-2017	2102	29.03	1694	23.39	2386	32.95	130	1.80	62	0.86	867	11.97
AUG-2017	2094	28.82	1687	23.22	2408	33.14	130	1.79	61	0.84	886	12.19
SEP-2017	2074	28.72	1676	23.21	2427	33.61	127	1.76	57	0.79	861	11.92
OCT-2017	2050	28.30	1674	23.11	2476	34.18	124	1.71	57	0.79	863	11.91
NOV-2017	2004	27.68	1668	23.04	2519	34.79	119	1.64	56	0.77	875	12.08
DEC-2017	1998	27.65	1660	22.97	2531	35.02	115	1.59	56	0.77	867	12.00
JAN-2018	2009	27.55	1645	22.56	2595	35.59	117	1.60	55	0.75	871	11.94
FEB-2018	1968	27.12	1630	22.46	2615	36.04	116	1.60	59	0.81	868	11.96
MAR-2018	1981	27.21	1616	22.19	2647	36.35	113	1.55	56	0.77	868	11.92
APR-2018	1939	26.69	1596	21.97	2698	37.13	114	1.57	58	0.80	861	11.85
MAY-2018	1932	26.51	1575	21.61	2738	37.57	114	1.56	58	0.80	871	11.95
JUN-2018	1913	26.22	1565	21.45	2791	38.26	113	1.55	58	0.80	855	11.72
JUL-2018	1889	25.89	1567	21.48	2817	38.62	110	1.51	55	0.75	857	11.75
AUG-2018	1865	25.59	1548	21.24	2858	39.22	110	1.51	56	0.77	850	11.66

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2017	21	3	2	3	6	6	390
FEB-2017	24	5	3	1	3	10	425
MAR-2017	19	5	3	5	2	2	220
APR-2017	20	1	2	6	5	5	350
MAY-2017	22	2	0	3	9	8	405
JUN-2017	24	6	2	5	3	7	230
JUL-2017	14	2	2	2	1	5	340
AUG-2017	25	4	0	4	3	12	510
SEP-2017	16	1	2	3	3	5	440
OCT-2017	6	2	0	0	1	2	450
NOV-2017	19	2	1	6	3	7	430
DEC-2017	18	2	2	4	4	5	390
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	22	4	1	5	4	7	350
APR-2018	14	0	0	4	3	4	400
MAY-2018	12	1	0	4	3	2	370
JUN-2018	16	3	5	1	1	6	237
JUL-2018	15	4	1	3	4	1	284
AUG-2018	27	2	2	6	4	12	450

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2017	11555	3375
FEB-2017	11580	3382
MAR-2017	11631	3431
APR-2017	11657	3446
MAY-2017	11698	3471
JUN-2017	11726	3486
JUL-2017	11758	3516
AUG-2017	11794	3543
SEP-2017	11821	3568
OCT-2017	11878	3622
NOV-2017	11890	3621
DEC-2017	11917	3627
JAN-2018	11975	3669
FEB-2018	12004	3683
MAR-2018	12032	3712
APR-2018	12062	3742
MAY-2018	12098	3767
JUN-2018	12110	3770
JUL-2018	12138	3796
AUG-2018	12156	3795

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants August 2018

N = 7287

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2018

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2018

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2018

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2018

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





**4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
INTERIOR Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	40	53	26
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	70	93	51	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	357	478	268	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	15
	35-49	*	*	45
	50+	*	*	84
Total HSDA:	187	248	144	
Total HA:		654	872	489

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		654	872	489

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	515	695	390
Female	139	177	99

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	489	54	610	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	*
	5 years or more	7	*
	<5 years	15	*
	Total HSDA:	40	26
KOOTENAY BOUNDARY	10 years or more	43	30
	5 years or more	14	11
	<5 years	13	10
	Total HSDA:	70	51
OKANAGAN	10 years or more	216	151
	5 years or more	64	55
	<5 years	77	62
	Total HSDA:	357	268
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	99	69
	5 years or more	40	34
	<5 years	48	41
	Total HSDA:	187	144
Total HA:		654	489

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	376	261
	5 years or more	125	104
	<5 years	153	124
Total HA:		654	489

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	39	57	12	21
KOOTENAY BOUNDARY	66	119	22	42
OKANAGAN	209	779	63	273
THOMPSON/CARIBOO/SHUSWAP	125	478	36	135
Total:	439	1433	133	471

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	89

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	5	5	5
	20-34	28	30	21
	35-49	114	125	80
	50+	210	281	165
	Total HSDA:		357	441
FRASER NORTH	0-19	10	10	*
	20-34	112	113	*
	35-49	346	381	*
	50+	524	831	*
	Total HSDA:		992	1335
FRASER SOUTH	0-19	7	7	*
	20-34	104	106	*
	35-49	342	394	*
	50+	496	734	*
	Total HSDA:		949	1241
Total HA:		2298	3017	1813

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	22	22	11
	20-34	244	249	175
	35-49	802	900	628
	50+	1230	1846	999
Total HA:		2298	3017	1813

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1752	2325	1411
Female	546	692	402

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1813	51	620	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	191	139
	5 years or more	95	74
	<5 years	71	58
	Total HSDA:	357	271
FRASER NORTH	10 years or more	512	371
	5 years or more	254	206
	<5 years	226	196
	Total HSDA:	992	773
FRASER SOUTH	10 years or more	489	388
	5 years or more	229	184
	<5 years	231	197
	Total HSDA:	949	769
Total HA:		2298	1813

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	1192	898
5 years or more	578	464
<5 years	528	451
Total HA:	2298	1813

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	136	480	38	82
FRASER NORTH	244	1515	55	232
FRASER SOUTH	209	1299	43	357
Total:	589	3294	136	671

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	203
FRASER NORTH	652
FRASER SOUTH	533
Total:	1388

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	19
	35-49	*	*	73
	50+	*	*	188
	Total HSDA:		329	474
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		162	211
VANCOUVER	0-19	37	40	6
	20-34	434	446	317
	35-49	1463	1653	1070
	50+	2697	4569	2058
	Total HSDA:	4631	6708	3451
Total HA:		5122	7393	3857

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	40	43	7
	20-34	485	498	353
	35-49	1592	1796	1177
	50+	3005	5056	2320
Total HA:		5122	7393	3857

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4499	6483	3398
Female	621	908	459

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3857	52	620	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	173	138
	5 years or more	76	67
	<5 years	80	75
	Total HSDA:	329	280
RICHMOND	10 years or more	84	63
	5 years or more	42	33
	<5 years	36	30
	Total HSDA:	162	126
VANCOUVER	10 years or more	2578	1853
	5 years or more	1204	899
	<5 years	849	699
	Never on ART	0	0
	Total HSDA:	4631	3451
Total HA:	5122	3857	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2835	2054
	5 years or more	1322	999
	<5 years	965	804
	Never on ART	0	0
Total HA:		5122	3857

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	163	476	56	178
RICHMOND	43	279	14	92
VANCOUVER	579	10577	206	5359
Total:	785	11332	276	5629

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	122

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		311	435
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		119	158
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		709	998
Total HA:		1139	1591	876

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	8	8	*
	20-34	100	106	*
	35-49	301	348	*
	50+	730	1129	*
Total HA:		1139	1591	876

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	934	1307	727
Female	205	284	149

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	876	54	520	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	162	131
	5 years or more	72	58
	<5 years	77	60
	Total HSDA:	311	249
NORTH VANCOUVER ISLAND	10 years or more	64	50
	5 years or more	31	21
	<5 years	24	18
	Total HSDA:	119	89
SOUTH VANCOUVER ISLAND	10 years or more	387	270
	5 years or more	165	139
	<5 years	157	129
	Total HSDA:	709	538
Total HA:		1139	876

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	613	451
	5 years or more	268	218
	<5 years	258	207
Total HA:		1139	876

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	189	829	78	195
NORTH VANCOUVER ISLAND	126	256	41	72
SOUTH VANCOUVER ISLAND	204	1715	43	554
Total:	519	2800	162	821

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	46
NORTH VANCOUVER ISLAND	33
SOUTH VANCOUVER ISLAND	104
Total:	183

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		41	49
NORTH WEST	0-19	*	*	0
	20-34	*	*	8
	35-49	*	*	14
	50+	*	*	28
	Total HSDA:		66	104
NORTHERN INTERIOR	0-19	5	5	*
	20-34	20	23	*
	35-49	72	88	*
	50+	86	141	*
	Total HSDA:		183	257
Total HA:		290	410	213

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	33	38	*
	35-49	107	142	*
	50+	143	223	*
Total HA:		290	410	213

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	178	255	132
Female	112	155	81

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	213	50	560	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	19	9
	5 years or more	14	9
	<5 years	8	5
	Total HSDA:	41	23
NORTH WEST	10 years or more	26	16
	5 years or more	26	23
	<5 years	14	11
	Total HSDA:	66	50
NORTHERN INTERIOR	10 years or more	67	48
	5 years or more	65	52
	<5 years	51	40
	Total HSDA:	183	140
Total HA:		290	213

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	112	73
	5 years or more	105	84
	<5 years	73	56
Total HA:		290	213

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	37	61	8	9
NORTH WEST	69	154	16	27
NORTHERN INTERIOR	103	438	15	189
Total:	209	653	39	225

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	18
NORTHERN INTERIOR	22
Total:	46

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	22	37	*
	THOMPSON/CARIBOO/SHUSWAP	26	43	*
	Total HA:	60	99	44
FRASER	FRASER EAST	41	51	32
	FRASER NORTH	51	85	42
	FRASER SOUTH	66	97	49
	Total HA:	158	233	123
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	26	49	22
	RICHMOND	11	16	10
	VANCOUVER	498	840	404
	Total HA:	535	905	436
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	50	77	39
	NORTH VANCOUVER ISLAND	16	25	11
	SOUTH VANCOUVER ISLAND	35	75	27
	Total HA:	101	177	77
NORTHERN	NORTH EAST	10	12	6
	NORTH WEST	31	60	26
	NORTHERN INTERIOR	65	100	54
	Total HA:	106	172	86
Total:		960	1586	766

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	598	1016	478
Female	362	570	288

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	766	51	500	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicstat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicstat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from ViiV Healthcare.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

